Findings: RCTSURMOUNT-2 trial - Tirzepatide vs Placebo for Weight Loss in Diabetes, Lancet (2023) [PubMed abstract] Design: Randomized, placebo-controlled trial (N=938 | length = 72 weeks) in overweight diabetics (mean BMI 36 | mean A1C 8.02%) Treatment: Tirzepatide 10 mg once weekly vs Tirzepatide 15 mg once weekly vs Placebo Primary outcome: Coprimary endpoints were the percent change in body weight from baseline and body weight reduction of 5% or higher Results: Primary outcome (% reduction in weight): Tirzepatide 10 mg - 12.8%, Tirzepatide 15 mg - 14.7%, Placebo - 3.2% (p 35 - 68.9% Randomized treatment groups Group 1 (374 patients): Tirzepatide titrated to the maximum tolerated dose of 10 mg or 15 mg once weekly Group 2 (376 patients): Semaglutide titrated to the maximum tolerated dose of 1.7 mg or 2.4 mg once weekly Tirzepatide was initiated at a dose of 2.5 mg once weekly, and the dose was increased by 2.5 mg every 4 weeks until a maximum tolerated dose of 10 mg or 15 mg was reached
Personas con un IMC de 27 o mayor que han presentado en el pasado las siguientes condiciones: Ataques cardacos
Milk Thistle Extract (Silybum marianum) (Fruit/Seeds) (Standardized to 80 mg Silymarin Flavonoids - equivalent 80%) 100 mg ** Daily Value not established
102 Therefore, CBD can have a therapeutic function in several conditions involving inflammation and oxidative stress, such as Parkinson's disease, 114,115 rheumatoid arthritis, 116 Alzheimer's disease, 117 ischemia-reperfusion injury, 118 metabolic diseases, 119,120 among others
